Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that its cash reserves have been further strengthened by the receipt of $2.16 million in research and development tax incentive for the 2023-24 financial year.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe today to attendees of the Bell Potter Healthcare Conference 2024.
TruScreen Group Limited (NZE:TRU) (ASX:TRU) is pleased to provide an update of its key markets and target markets.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the Chairman's Address to be provided by Mr Neville Gardiner and the Investor Presentation to be provided by Dr Richard Lipscombe to shareholders.
Proteomics International Laboratories Ltd (ASX:PIQ) today announces the appointment of Aaron Brinkworth to its Board as independent, non-executive Director, in concert with the retirement of Roger Moore as non-executive Director.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics and precision medicine is pleased to provide the following update on its business activities for the three months to 30 September 2024 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce the publication of groundbreaking results showing the PromarkerD predictive test can predict renal decline in type 1 diabetes.
